# Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

> **NCT01309997** · PHASE2 · COMPLETED · sponsor: **Lee, Stephanie** · enrollment: 72 (actual)

## Conditions studied

- Graft Versus Host Disease
- Systemic Scleroderma

## Interventions

- **DRUG:** imatinib mesylate
- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT01309997
- **Lead sponsor:** Lee, Stephanie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-12
- **Final completion:** 2015-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2016-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309997, "Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01309997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*